Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study

You may be eligible if

• Histologically or cytologically diagnosed NSCLC, all histologies are acceptable.
• Patients can be included in the study with any disease stage and at any time during the disease course.
• Any type (surgery, RadioTherapy, chemotherapy, targeted agents) of previous treatment and any line of treatment are eligible.
• Age ≥18 years.
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient before registration in the trial.
• Before patient registration, written informed consent must be given according to ICH/GCP (International Conference on Harmonisation/Good Clinical Practice), and national/local regulations.